businessbriefs
10:10in productionCh. 1 · Basel, not Boston/ 10:10 · ceiling 15 min
Companies

Roche

1896

Roche isn’t a biotech pioneer — it’s a precision acquirer that turns diagnostics and drugs into a single revenue stream.

Roche is a Swiss multinational holding healthcare company founded in 1896, headquartered in Basel, operating through Pharmaceuticals and Diagnostics divisions. It is the fifth-largest pharmaceutical company by revenue and the global leader in cancer treatments. It owns Genentech, Chugai Pharmaceuticals, Ventana, and Foundation Medicine as subsidiaries. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. In 2023, it ranked 76th in the Forbes Global 2000.

CompaniesMedicinePhotographyChemistryMedicine across the network →
Chapters & takeaways4
  1. 0:46
    Basel, not Boston

    Roche is a Swiss holding company headquartered in Basel — not a startup, not a foundation, but a century-old corporate structure built for scale.

  2. 2:26
    Fifth by revenue, first in cancer

    It ranks fifth by pharmaceutical revenue and leads globally in cancer treatments — but those are separate metrics, not proof of market control across oncology.

  3. 5:17
    Owned, not partnered

    Genentech and Chugai are wholly owned subsidiaries — meaning Roche absorbs their R&D costs and captures their profits, but also bears their regulatory and commercial risks.

  4. 6:30
    Listed, ranked, consolidated

    Its shares trade on the SIX Swiss Exchange, and its Forbes Global 2000 rank (76th in 2023) reflects consolidated financials — not standalone pharmaceutical or diagnostics performance.

Worth your time?

Yes. Study the whole thing.

4/ 5
What works
  • Dual-division structure aligning drug and diagnostic development.
  • Acquisition and integration of specialised biotech and diagnostics firms.
  • Global commercial infrastructure supporting high-cost targeted therapies.
What does not
  • Roche's leadership in cancer treatments extends to all oncology indications.
  • Roche controls pricing or reimbursement decisions in national health systems.
Study it if
  • Healthcare investors assessing vertical integration.
  • Regulatory analysts studying companion diagnostics pathways.
  • Strategy teams benchmarking acquisition-led growth in pharma.
Skip it if
  • Startups seeking validation of disruptive biotech models.
  • Policy makers looking for alternatives to patent-driven innovation.
The written brief1 min read

What the company or idea is

Roche is a Swiss multinational holding healthcare company founded in 1896, headquartered in Basel, with publicly listed shares on the SIX Swiss Exchange.

How it actually makes money

Roche makes money through two divisions: Pharmaceuticals and Diagnostics. Its revenue comes from selling cancer treatments, diagnostic instruments and tests, and related services globally.

What works

Its dual-division structure links drug development with diagnostic testing, enabling companion diagnostics that support regulatory approval and clinical adoption of targeted therapies.

What does not

Roche does not control pricing or reimbursement decisions in most national health systems. Its leadership in cancer treatments does not extend to all oncology indications or to early-stage prevention.

What to take from it

Roche shows how a century-old firm sustains dominance not through innovation alone, but by acquiring and integrating specialised biotech and diagnostics firms — Genentech, Chugai, Ventana, Foundation Medicine — into a coordinated commercial engine.

Is it worth your time

Yes — if you are assessing how scale, vertical integration, and acquisition strategy operate in regulated healthcare markets.

Same desk · Companies4 of 325
10:34
Novo Nordisk1923Novo Nordisk is a Danish multinational pharmaceutical company, founded in 1989 through the merger of two 1920s-origin insulin firms. It manufactures and markets pharmaceutical products and services, primarily for diabetes and obesity. Its first major device innovation was the Novopen insulin pen, launched in 1985. The 1989 merger made it the world’s largest insulin producer. Its headquarters are in Bagsværd.
10:30
AstraZeneca1913AstraZeneca is a Swedish–British multinational pharmaceutical and biotechnology company founded in 1999 through the merger of Swedish Astra AB and British Zeneca Group. Its global headquarters are located in the Cambridge Biomedical Campus in Cambridge, England. It develops, manufactures and sells pharmaceutical and biotechnology products to treat disorders in oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation.
11:20
Novartis1996Novartis is a Swiss multinational pharmaceutical corporation formed in 1996 by the merger of Ciba-Geigy and Sandoz. It operates as a publicly traded holding company with two main divisions — Innovative Medicines and Sandoz — and manufactures numerous branded drugs including clozapine, valsartan, imatinib mesylate, and cyclosporine. The merger combined the pharmaceutical and agrochemical divisions of the predecessor firms into an independent entity, and the company has since undergone extensive restructuring, acquisitions, divestitures, and spin-offs — including Alcon (spun off in 2019) and Sandoz (spun off in October 2023).
10:44
Lupin (company)1968Lupin is not a story of startup disruption. It is a story of therapeutic specialisation, state procurement, and incremental geographic expansion — all executed through generic drug manufacturing.
Up next in Business

Rolex

Hans Wilsdorf · 1905 · 11:01

Rolex didn’t win the luxury watch race by selling dreams — it won by certifying time, replacing watches for POWs, and controlling every gear in between.

Play nextBack to Companies
11:01